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INTRODUCTION 
Visna virus is the prototype of the lentivirus subgroup 
of retroviruses. Lentivirus means slow virus; this refers 
to the fact that visna virus causes a slow infection in 
sheep which leads either to the lung disease maedi or 
more rarely to the central nervous system (CNS) disease 
visna. 
Maedi, meaning shortness of breath, is a slow 
progressive lymphoid interstitial pneumonia which was 
first described in South Africa and in Montana in the 
USA 80 years ago. Since then it has been found to be 
endemic in many countries in Europe and Asia [l]. 
Visna, which is a slowly progressing leukoencephalo- 
myelitis, is rarely seen even in areas where the lung 
disease is prevalent. Thus, in a flock of sheep with 
endemic slow progressive pneumonia in the Rocky 
Mountains, where 76% of the sheep were affected by 
the lung disease, only 7% showed lesions in the CNS 
Maedi was brought to Iceland with sheep imported 
from Germany in 1933 and caused a widespread 
epidemic in Icelandic sheep in the following two 
decades. In contrast to the experience in other 
countries, a large number of cases with CNS disease 
were seen in one area of Iceland where maedi was 
prevalent. The CNS disease was named visna, which 
means wasting. In Icelandic sheep, visna was charac- 
terized by loss of motor function, particularly in the 
hind limbs, which progressed to paralysis and ended in 
death. It  is still not known what caused this difference 
in the neuropathogenicity of the infection in Iceland 
compared with other countries, and whether it was 
determined by host or viral factors, although the latter 
is considered more likely. 
(21. 
Visna virus was isolated in Iceland in 1957 in tissue 
culture from an infected sheep brain. In the following 
year, the same virus was isolated from lungs of sheep 
with maedi, but the lung isolates were slightly different 
from the brain isolates. From these and other obser- 
vations it was concluded that visna and maedi are 
caused by the same virus and that visna is a neurologic 
manifestation of the more common lung disease [3]. 
Visna virus is therefore often referred to as maedi/visna 
virus (MVV). Further characterization of the virus 
showed it to resemble avian and niurine leukemia 
viruses, and shortly after the demonstration of reverse 
transcriptase (RT) in the virions of these viruses, RT 
was also found in visna virions [4]. The molecular 
biology of visna virus and its virus-host interactions 
have since then been thoroughly studied in Iceland and 
in several laboratories both in Europe and the USA. All 
of these studies demonstrated that visna virus, and the 
related viruses CAEV (caprine arthritis encephalitis 
virus) and EIAV (equine infectious anemia virus), are 
non-oncogenic retroviruses which were classified as the 
lentivirus subgroup of retroviruses [S]. 
When the human immunodeficiency virus (HIV) 
was isolated in 1983 it soon became apparent that it 
fitted into the lentivirus subgroup [6]. Studies of visna 
virus thus gained increased importance because of i ts  
similarity to HIV. There is a considerable homology in 
the genomes of the two viruses, particularly in the P O I  
genes but also in the gug genes. The gene organization 
is similar and the viruses share at least three non- 
structural regulatory genes with apparently identical 
functions. The replication cycle of visna virus is 
functionally very similar to that of HIV, and both 
viruses infect monocytes and macrophages. However, 
they use different cell receptors and visna virus does not 
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infect T-helper cells or cause noticeable immuno- 
deficiency. In the infected host, both viruses show an 
acute phase early in the infection followed by a 
prolonged period of clinical latency, sometimes lasting 
for several years. When clinical signs appear, they are 
progressive and always lead to death. HIV and visna 
virus infections cause similar pathologic changes in the 
lungs and in the CNS, at least early in the disease, and 
the immune response is not effective in clearing the 
infection [7,8]. 
EFFECT OF ANTI-HIV COMPOUNDS ON VISNA VIRUS 
REPLICATION IN CELL CULTURE 
Compounds which are active against HIV and other 
lentiviruses of primates have been thoroughly studied. 
In contrast, few studies have been done on compounds 
that are active against visna virus and related lentiviruses 
of ungulates. However, it is of interest to compare 
the drug sensitivities of the primate and ungulate 
lentiviruses to further characterize their molecular and 
biological relationships. Also, compounds that strongly 
affect the replication of both subgroups of lentiviruses 
may be considered to be broad-spectrum lentivirus 
inhibitors. Finally, because of the similar neuropathic 
effects of visna virus and HIV, the visna disease in sheep 
might be used as an animal model for in vivo testing of 
candidate anti-HIV drugs, particularly with regard to 
their potential efficacy in the treatment of HIV 
infections of the brain. 
Experiments were therefore done to test the effect 
of various anti-HIV drugs on the replication of visna 
virus in sheep choroid plexus (SCP) cell culture [9,10]. 
Sulfated polysaccharides (i.e. dextran sulfate, pentosan 
polysulfate and heparin) and various plant lectins were 
found to be 10-40-fold less active against visna virus 
than HIV under the experimental conditions used. 
Since both types of compounds are known to inhibit 
viral adsorption and/or fusion to host cell membranes, 
the results may reflect differences in the surface proteins 
of the viruses. TIBO derivatives, which are non- 
nucleoside RT inhibitors with a high specificity 
for HIV-1, had no inhibitory effect on visna virus 
at subtoxic concentrations. The same was true for 
bicyclam derivatives, which are also highly HIV- 
specific compounds, supposedly affecting the fusion of 
the virus [ll].  In contrast, certain nucleoside analogs 
which are inhibitors of HIV RT were found to be very 
active against visna virus replication. This was parti- 
cularly true for 2', 3'-dideoxynucleoside (ddN) and 
acyclic nucleoside phosphonate (ANP) analogs [9,10]. 
Of  the ddN analogs, dideoxycytidine (ddC) and 
dideoxyinosine (ddI) were the most active, whereas 
9-(2-phosphonomethoxyethyl)adenine (PMEA) and 
(R)-9-(2-phosphonomethoxypropyl)adenine (PMPA) 
were among the most active ANP analogs. Both of 
these compounds are also highly active against HIV 
[ l l ] .  A summary of these results is shown in Table 1. 
EFFECT OF PMEA ON VlSNA VIRUS INFECTION IN 
LAMBS 
In order to investigate the feasibility of using visna in 
sheep as an animal model for testing the in vivo efficacy 
of anti-HIV compounds, it was decided to study the 
effect of the prototype ANP analog PMEA on the early 
stages of visna virus infection in young lambs. PMEA 
had previously been tested against several other retro- 
virus infections in experimental animals by admini- 
stration of the drug simultaneously with or slightly 
before inoculation with virus [12]. For the sake of 
comparison, a similar protocol was used in the visna 
virus experiment [ 131. In this experiment, 2-week-old 
Icelandic lambs were inoculated intracerebrally with 
106.3 TCIDso (50% tissue-culture infective dose) of 
visna virus KV1772, which is a biological clone with 
increased neurovirulence. Two groups of four lambs 
each received PMEA subcutaneously 1 h before 
intracerebral inoculation, at  10 and 25 mg/kg, respec- 
tively, and the drug treatment was continued for 
6 weeks, with subcutaneous injections three times a 
week. A group of four lambs was inoculated in the same 
way but not treated with PMEA. The lambs were bled 
at  regular intervals and the leukocytes tested for the 
presence of visna virus. At 7 weeks after infection, the 
animals were killed, and cerebrospinal fluid (CSF) and 
samples of tissue from various organs were collected for 
isolation of virus and for histopathologic examination. 
Table 2 summarizes the results of this experiment [13]. 
The PMEA treatment had an inhibitory effect on 
the visna virus infection, which was similar for both 
doses of the drug. Thus, the frequency of virus 
isolations was much lower in PMEA-treated than 
in untreated lambs. This difference was particularly 
Table 1 A summary of the inhibitory effects of anti-HIV 
compounds on visna virus replication in SCP cell cultures 
Compound Anti-visna virus effect 
Sulfated polysaccharides (+) 
Plant lectins (+) 
Bicyclam derivatives - 
Dideoxynucleoside analogs + 
Acyclic nucleoside phosphonates + 
- TIBO derivatives 
+, compound equally active against visna virus and HIV; 
(+), compound less active against visna virus than against HIV 
-, compound not effective or with a negligible effect on visna 
nrus. 
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Table 2 Effect of PMEA treatment on visna virus infection 
in lambs 
Frequency of virus isolationsa 
Brain lesions, 
Group" PBMC' Brain Other organsd average grade' 
I 16/24 (67%) 13/18 (72%) 15/16 (94%) 3.0 
111 0/24 (0%) 5/20 (25%) 7/14 (50%) 0.375 
I1 1/24 (4%) 2/19 (11%) 7/14 (50%) 0.5 
'The results are expressed as no. positivelno. tested and per cent 
positive (in parentheses). 
"The lambs were either untreated (group I) or injected 
subcutaneously with PMEA at 10 mg/kg (group 11) or 25 mg/kg 
(group 111) three times weekly for 6 weeks. 
'Peripheral blood mononuclear cells. 
"Lungs, spleen, cervical lymph node, niediastinal lymph node. 
'The severity of inflammatory brain lesions is graded on a scale of 
0-6. 
pronounced in the peripheral blood mononuclear cells 
(PBMCs) and in brain tissue. Furthermore, inflam- 
matory lesions in the brain were much less severe and 
the cell counts in the CSF and the serum antibody titers 
against visna virus were much lower (data not shown) 
in the treated lambs than in the untreated controls. 
The inhibitory effect of PMEA on visna virus 
infection in lambs is in agreement with previous studies 
of this anti-HIV compound in other animal models, 
where treatment began 1-48 h before virus inoculation 
[12]. The efficacy of PMEA treatment in reducing 
early inflammation in the brain of visna virus-infected 
lambs is particularly noticeable. This correlates with a 
considerably lower viral activity in the brains of treated 
compared with untreated animals. 
A pharmacokinetic study of PMEA in the blood of 
the two groups of lambs, receiving a dose of 25 or 
10 mg/kg, showed half-lives of the drug of 75 and 
64 niin, respectively. The drug caused no noticeable 
side effects during the 6 weeks of treatment. 
Because of this marked prophylactic effect of 
I'MEA treatment on visna virus infection in lambs and 
its safety during an extended treatment period, it was 
of interest to study the possible therapeutic effect of 
such treatnient in later phases of the infection, when 
inflarnniatory brain lesions had already appeared. A 
number of young lambs were therefore inoculated with 
visna virus as in the first experiment, but treatment 
with I'MEA was not started until 1 month later. The 
treatment was continued for 8 months, with three 
subcutaneous injections a week. The dose was 
10  nig/kg during the first 6 months, but was increased 
to 25 mg/kg for the final 2 months of the treatment. 
The sheep were then killed and samples taken from the 
brain, lungs, spleen and lymph nodes for virus isolation. 
The results of this experiment [I41 show that the 
PMEA treatment had inuch less effect than in the 
previous experiment, where treatment was begun 1 h 
before inoculation. Although there was a significant 
reduction in the number of virus isolations from 
the PBMCs of PMEA-treated lambs conipared with 
untreated lambs (P<0.05),  there was no difference in 
the number of virus isolations from brains and other 
organs collected at sacrifice, 8 months after beginning 
treatment, and there was no difference in CSF cell 
counts. Thus, the PMEA treatment which was started 
4 weeks after inoculation with visna virus had only a 
minimal therapeutic effect on the virus infection in 
lambs. These results are in agreement with a recent 
study on the therapeutic effect of PMEA in cats with 
chronic feline immunodeficiency virus infection 1151. 
In this study, no detectable reduction was found in the 
viral load in plasma after subcutaneous injection of 
20 mg/kg of PMEA three times a week for 6 weeks 
1151. O n  the other hand, in a study 011 the efficacy 
of PMEA treatment against chronic simian inimuno- 
deficiency virus infection in macaques, the drug caused 
a marked reduction in viral load in the blood and the 
number of viral isolations from PBMCs [ 1 61. However, 
although the drug was administered subcutaneously at 
a dose of20 mg/kg daily for 4-8 weeks, it had no effect 
on the tissue distribution of the virus tested at various 
times after the end of PMEA treatment. 
SUMMARY AND CONCLUSIONS 
Visna virus is a lentivirus of sheep which shows 
molecular and biological similarities to HIV. Nucleoside 
analogs which are inhibitors of HIV RT were found to 
be highly effective inhibitors of visna virus replication 
in vitro. The acyclic nucleoside phosphonate analog 
PMEA was tested against visna virus infection in lambs. 
The drug was very effective against the brain infection 
if administered 1 h before intracerebral inoculation 
with visna virus. O n  the other hand, it showed little 
activity if treatment was begun 1 month after inocula- 
tion. This is in agreement with studies of PMEA 
treatment in other lentivirus infections, where a 
comparable dose was used. Visna virus infection in 
lambs therefore seems to be a useful aniinal model 
to study the effect of drug treatment on lentivirus 
infections of the brain, particularly in short-term 
experiments. 
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